hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06329687, orgStudyIdInfo id: OPP-010, briefTitle: A Study Evaluating the Safety of the Nasal Pump, statusModule overallStatus: TERMINATED, startDateStruct date: 2024-02-21, primaryCompletionDateStruct date: 2024-02-28, completionDateStruct date: 2024-02-28, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Oyster Point Pharma, Inc., class: INDUSTRY, descriptionModule briefSummary: The objective of this study is to determine the safety of the Tyrvaya nasal pump., conditionsModule conditions: Dry Eye, conditions: Kerato Conjunctivitis Sicca, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 5, type: ACTUAL, armsInterventionsModule interventions name: Tyrvaya Nasal Pump, outcomesModule primaryOutcomes measure: Incidence of Adverse Events, otherOutcomes measure: Tear Film Break up Time, otherOutcomes measure: Eye Dryness Score, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: United States, California, city: Newport Beach, state: California, zip: 92663, country: United States, geoPoint lat: 33.61891, lon: -117.92895, hasResults: False
protocolSection identificationModule nctId: NCT06329674, orgStudyIdInfo id: 20DM30203, briefTitle: Efficacy and Safety of AJU-A51 in Type 2 Diabetes Mellitus Patients, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-04-27, primaryCompletionDateStruct date: 2022-12-01, completionDateStruct date: 2023-06-13, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: AJU Pharm Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: A multicenter, randomized, double-blind, parallel group, placebo-controlled, phase 3 study to evaluate the efficacy and safety of the combination of A51R3 and AJU-A51 compared with the combination of A51R3 and A51R2 in patients with Type 2 diabetes mellitus who have inadequate glycemic control with the combination of A51R3 and A51R2, conditionsModule conditions: Type2 Diabetes, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 235, type: ACTUAL, armsInterventionsModule interventions name: AJU-A51, interventions name: A51R2, interventions name: A51R3, interventions name: AJU-A51 Placebo, interventions name: A51R2 Placebo, outcomesModule primaryOutcomes measure: Changes in HbA1c, eligibilityModule sex: ALL, minimumAge: 19 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Asan Medical Center, city: Seoul, country: Korea, Republic of, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06329661, orgStudyIdInfo id: CYS-007, briefTitle: A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-30, primaryCompletionDateStruct date: 2025-11-30, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Novaliq GmbH, class: INDUSTRY, descriptionModule briefSummary: The objective of this trial is to evaluate the effect of cyclosporine ophthalmic solution, 0.1% on corneal endothelial cell health in comparison to a hypotonic saline solution in subjects with Dry Eye Disease (DED), conditionsModule conditions: Dry Eye Disease, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Cyclosporine ophthalmic solution, 0.1% (VEVYE), interventions name: Saline solution, 0.6%, outcomesModule primaryOutcomes measure: Change from baseline in corneal ECD, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06329635, orgStudyIdInfo id: 2023070K, briefTitle: Treatment of Vasospasm of Aneurysmal Subarachnoid Hemorrhage With Intrathecal Nicardipine - FAST-IT Trial, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-04, completionDateStruct date: 2026-04, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: The Affiliated Hospital Of Guizhou Medical University, class: OTHER, descriptionModule briefSummary: To investigate whether patients with cerebral vasospasm associated with aneurysmal subarachnoid hemorrhage have a better prognosis with intrathecal nicardipine injection via extraventricular drainage or lumbar drainage., conditionsModule conditions: Aneurysmal Subarachnoid Hemorrhage, conditions: Vasospasm, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, maskingDescription: The assigned "intervention" will be performed only by a separate unblinded dedicated physician who signs the confidential agreement. The attending/investigating physician and patient are blinded to the intervention assignment., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 396, type: ESTIMATED, armsInterventionsModule interventions name: Intrathecal Nicardipine, interventions name: No intervention, outcomesModule primaryOutcomes measure: Dichotomized Modified Rankin Scale (mRS) 0-2 vs 3-6, secondaryOutcomes measure: Extended Glasgow Outcome Score (GOS-E)., secondaryOutcomes measure: Modified Rankin Scale ordinal shift with mRS 5 and 6 combined, secondaryOutcomes measure: Dichotomized Modified Rankin Scale (mRS) 0-3 vs 4-6, secondaryOutcomes measure: Hamilton Depression Rating Scale (HAM-D) score, secondaryOutcomes measure: Hamilton Anxiety Rating Scale (HAM-A) score, secondaryOutcomes measure: Mini-Mental State Examination (MMSE) score, secondaryOutcomes measure: Montreal Cognitive Assessment (MoCA) scale score, secondaryOutcomes measure: Change of National Institutes of Health Stroke Scale (NIHSS) score, secondaryOutcomes measure: Cerebrospinal fluid shunt surgery rate, secondaryOutcomes measure: Overall mortality rate, secondaryOutcomes measure: Rate of CSF infection, secondaryOutcomes measure: Rate of any type of new intracranial hemorrhage., secondaryOutcomes measure: Adverse Event, secondaryOutcomes measure: Serious Adverse Event, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06329622, orgStudyIdInfo id: KY2023-972, briefTitle: Effect of Ketosteril on Sarcopenia in Patients With Chronic Kidney Disease, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-06-30, completionDateStruct date: 2026-06-30, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Huashan Hospital, class: OTHER, descriptionModule briefSummary: The investigators hypothesize that Ketosteril can improve sarcopenia in patients with renal disease without increasing the burden on the kidneys and causing deterioration of renal function. Therefore, this study intends to take patients with CKD stage 3-4 and sarcopenia as the research object, give Ketosteril intervention or not to patients on the base of low-protein diet, and clarify the clinical benefits of Ketosteril prescription for improving sarcopenia in patients with CKD., conditionsModule conditions: Chronic Kidney Disease, conditions: Sarcopenia, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 58, type: ESTIMATED, armsInterventionsModule interventions name: low-protein diet + Ketosteril, interventions name: low-protein diet, outcomesModule primaryOutcomes measure: skeletal muscle mass index (SMI), secondaryOutcomes measure: changes in eGFR(ml/min/1.73m2), secondaryOutcomes measure: serum albumin(g/l), secondaryOutcomes measure: grip strength(kg), secondaryOutcomes measure: BMI(kg/m2), secondaryOutcomes measure: 6m walking speed(s), eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Nephrology, Huashan hospital, city: Shanghai, zip: 200040, country: China, contacts name: Mengjing Wang, role: CONTACT, phone: +8613764676029, email: fiyona27@126.com, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06329609, orgStudyIdInfo id: ClA-333, briefTitle: Airvo 3 Respiratory Rate Validation Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-10, completionDateStruct date: 2024-10, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Fisher and Paykel Healthcare, class: INDUSTRY, descriptionModule briefSummary: This is a clinical performance testing to validate the accuracy of the Airvo 3 device with respiratory rate algorithm manufactured by Fisher \& Paykel Healthcare for continuous respiratory rate monitoring., conditionsModule conditions: COPD, conditions: Healthy Volunteers, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Airvo 3 with respiratory rate algorithm, outcomesModule primaryOutcomes measure: Respiratory rate, secondaryOutcomes measure: Respiratory rate, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Element Boulder, city: Louisville, state: Colorado, zip: 80027, country: United States, contacts name: Monica Rabanal, MSc, BSN, role: CONTACT, email: monica.rabanal@element.com, contacts name: Blair Holman, MS, role: CONTACT, phone: +1 651 379 5549, email: Blair.Holman@element.com, contacts name: Monica Rabanal, MSc, BSN, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.97776, lon: -105.13193, hasResults: False
protocolSection identificationModule nctId: NCT06329596, orgStudyIdInfo id: H-55146, secondaryIdInfos id: D43TW012274, type: NIH, link: https://reporter.nih.gov/quickSearch/D43TW012274, briefTitle: Microbiome Alterations With Xylitol (MAX) in Pregnancy, acronym: MAX, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-03-31, completionDateStruct date: 2026-03-31, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Baylor College of Medicine, class: OTHER, collaborators name: Fogarty International Center of the National Institute of Health, collaborators name: University of Washington, collaborators name: Baylor College of Medicine Children's Foundation Malawi, descriptionModule briefSummary: The purpose of this study is to understand if chewing xylitol-gum initiated before 20 weeks of pregnancy and continued until delivery affects the bacteria that are found in the oral and vaginal cavities, signs of inflammation within the gingiva of the oral cavity, the health of the tissues in the mouth (clinical parameters of periodontal disease), and the bacteria in the mouth and gut of newborns among pregnant individuals in Malawi., conditionsModule conditions: Dysbiosis, conditions: Inflammation Gum, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: TRIPLE, maskingDescription: Participants, data collectors (i.e. dental officers, study staff members, clinical officers), and data analysts will be blinded (triple-blinded) to group allocation throughout the study., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Xylitol gum, interventions name: Sorbitol gum, outcomesModule primaryOutcomes measure: Periodontal disease at 28-30 weeks of pregnancy, secondaryOutcomes measure: Periodontal disease at 6 weeks postpartum, secondaryOutcomes measure: Alterations in the maternal oral microbiome communities delivery, secondaryOutcomes measure: Alterations in the maternal vaginal microbiome communities, secondaryOutcomes measure: Inflammatory mediator changes in the maternal gingival crevicular fluid at, secondaryOutcomes measure: Alterations within the infants' oral microbiome communities, secondaryOutcomes measure: Alterations within the infants' gut microbiome communities, eligibilityModule sex: FEMALE, minimumAge: 12 Years, maximumAge: 60 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Area 25 Health Center, city: Lilongwe, country: Malawi, contacts name: Benjamin Shayo, role: CONTACT, phone: +265980888996, email: benjamin.shayo@bcm.edu, geoPoint lat: -13.96692, lon: 33.78725, hasResults: False
protocolSection identificationModule nctId: NCT06329583, orgStudyIdInfo id: 23-012635, briefTitle: Establishing Pressures at the EGJ During Diaphragmatic Breathing Using High-resolution Esophageal Manometry, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, descriptionModule briefSummary: The goal of this study is to determine which position, maneuvers or combination thereof generates the highest pressure at the EGJ as assessed by high-resolution esophageal manometry and thus greater or more robust contraction of the diaphragm., conditionsModule conditions: Gastroesophageal Reflux, conditions: Dysphagia, conditions: Esophageal Motility Disorders, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: diaphragmatic breathing, outcomesModule primaryOutcomes measure: Pressure at the esophagogastric junction, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06329570, orgStudyIdInfo id: NF-2023-03, briefTitle: Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2027-03-31, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: NaviFUS Corporation, class: INDUSTRY, collaborators name: NaviFUS US LLC, descriptionModule briefSummary: This will be a prospective, open-label, single-arm pilot study to investigate the safety and efficacy of Bevacizumab (BEV) in combination with microbubble (MB)-mediated FUS in patients with recurrent GBM. BEV represents the physician's best choice for the standard of care (SoC) in rGBM after previous treatment with surgery (if appropriate), standard radiotherapy with temozolomide chemotherapy, and with adjuvant temozolomide., conditionsModule conditions: Glioblastoma Multiforme, conditions: Glioblastoma, conditions: Glioma, conditions: Brain Tumor, conditions: Neoplasms, conditions: Neoplasms, Nerve Tissue, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: NaviFUS System, interventions name: Lumason, interventions name: Bevacizumab, outcomesModule primaryOutcomes measure: Adverse Events (AEs), secondaryOutcomes measure: 6-month Progression-Free Survival (PFS-6), secondaryOutcomes measure: Progression-Free Survival (PFS), secondaryOutcomes measure: One-year Survival Rate, secondaryOutcomes measure: Overall Survival (OS), secondaryOutcomes measure: Objective Response Rate (ORR), secondaryOutcomes measure: Clinical Benefit Rate (CBR), secondaryOutcomes measure: Local Disease Control on the MRI Images, secondaryOutcomes measure: Corticosteroid Consumption, secondaryOutcomes measure: Quality of life (QoL) assessment, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Virginia, city: Charlottesville, state: Virginia, zip: 22903, country: United States, contacts name: Jason Sheehan, M.D., Ph.D., role: CONTACT, phone: 434-924-8129, email: JPS2F@uvahealth.org, contacts name: Arthur Lung, Ph.D., role: CONTACT, phone: 02-25860560, phoneExt: 180, email: arthur.lung@navifus.com, geoPoint lat: 38.02931, lon: -78.47668, hasResults: False
protocolSection identificationModule nctId: NCT06329557, orgStudyIdInfo id: 23-007188, briefTitle: Optimizing the Patient Experience Through Provider Coaching or Communication Intervention, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-03-08, primaryCompletionDateStruct date: 2025-02, completionDateStruct date: 2026-02, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, descriptionModule briefSummary: Hypothesis: Clinicians who receive patient experience coaching or communication classes have improved patient satisfaction scores and improved clinician satisfaction., conditionsModule conditions: Patient Satisfaction, conditions: Communication, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: Intervention 1, outcomesModule primaryOutcomes measure: To identify if patient experience coaching or communication classes have an effect on patient satisfaction scores and clinician satisfaction., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic in Rochester, city: Rochester, state: Minnesota, zip: 55905, country: United States, geoPoint lat: 44.02163, lon: -92.4699, locations facility: Mayo Clinic, city: Rochester, state: Minnesota, zip: 55905, country: United States, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False
protocolSection identificationModule nctId: NCT06329531, orgStudyIdInfo id: 2022-0992, secondaryIdInfos id: NCI-2024-02555, type: OTHER, domain: NCI-CTRP Clinical Registry, briefTitle: Validation of the Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS) Tool for Use in a Physical Medicine Rehabilitation Clinic, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2025-04-22, completionDateStruct date: 2025-04-22, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: M.D. Anderson Cancer Center, class: OTHER, descriptionModule briefSummary: To compare the results of the SOCS-OTS to another standardized screening measure that is currently being used by rehabilitation services at MD Anderson Cancer Center and to ensure that the SOCS-OTS correctly identifies those individuals needing OT services in cancer care., conditionsModule conditions: Cancer, conditions: Occupational Therapy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS), outcomesModule primaryOutcomes measure: Safety and adverse events (AEs), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: MD Anderson Cancer Center, city: Houston, state: Texas, zip: 77030, country: United States, contacts name: Ekta Gupta, MD, role: CONTACT, phone: 713-745-2327, email: egupta@mdanderson.org, contacts name: Ekta Gupta, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 29.76328, lon: -95.36327, hasResults: False
protocolSection identificationModule nctId: NCT06329518, orgStudyIdInfo id: HHC-2024-0064, briefTitle: Rezafungin PK in Patients on ECMO, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-04, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Hartford Hospital, class: OTHER, collaborators name: Melinta Therapeutics, LLC, descriptionModule briefSummary: Extracorporeal membrane oxygenation (ECMO) is a form of cardiopulmonary life-support for critically ill patients where blood is extracted from the vascular system and circulated by a mechanical pump while it is oxygenated and reinfused into the patient's circulation. It is well known that critically ill patients may experience alterations in antibiotic pharmacokinetics, and as a result, dosing modifications are generally required. There is a need to understand how ECMO circuits affect the pharmacokinetics and disposition of drugs. This study is designed to assess the pharmacokinetics of the new broad-spectrum echinocandin, Rezafungin, in critically ill patients receiving ECMO, conditionsModule conditions: Sepsis, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 8, type: ESTIMATED, armsInterventionsModule interventions name: Rezafungin, outcomesModule primaryOutcomes measure: Rezafungin Clearance, secondaryOutcomes measure: Rezafungin Area Under the Curve (AUC), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hartford Hospital, city: Hartford, state: Connecticut, zip: 06102, country: United States, geoPoint lat: 41.76371, lon: -72.68509, hasResults: False